Equity Overview
Price & Market Data
Price: $2.08
Daily Change: -$0.11 / 5.29%
Daily Range: $2.04 - $2.21
Market Cap: $628,743,808
Daily Volume: 399,256
Performance Metrics
1 Week: 5.56%
1 Month: -2.79%
3 Months: -8.33%
6 Months: -8.33%
1 Year: 37.50%
YTD: -6.70%
Company Details
Employees: 204
Sector: Health technology
Industry: Biotechnology
Country:
Details
ProKidney Corp., a clinical-stage biotechnology company, develops a cell therapy platform for the treatment of multiple chronic kidney diseases in the United States. Its lead product candidate, rilparencel, includes autologous selected renal cells (SRC) in Phase 3 and Phase 2 clinical studies in subjects with moderate to severe chronic kidney disease and diabetes. The company also develops a cryopreserved version of rilparencel that allows for long-term product preservation to be used in Phase 2 and 3 trials of rilparencel. ProKidney Corp. was founded in 2015 and is headquartered in Winston-Salem, North Carolina.